On October 1st, 2014, Wako Pure Chemical Industries, Ltd. (“WAKO”) and API Corporation (“API“) concluded a contract granting the license for
manufacture, sales and supply of Y-27632 used for research purposes. WAKO has been involved in Y-27632 business since 2003, and this new contract enables
WAKO to expand its Y-27632 business worldwide from this October. Since API discontinues its Y-27632 business by concluding this contract, WAKO is expecting
to receive orders not only from existing customers of API and Wako but also from new customers.
Y-27632, originally synthesized by Mitsubishi Tanabe Pharma Corporation, is a selective and a strong ROCK inhibitor which activates the ROCK signal cascade.
It has been commonly used in regenerative medical research due to increasing viability and cloning efficiency of human ES/iPS cells after cryopreservation.
⇒ LINK to Y-27632 homepage
⇒ LINK to
Reagents for ES·iPS Cell Culture [Catalog]
Wako Pure Chemical Industries, Ltd. International Sales Section